Wilson Sonsini Expands Healthcare Regulatory Practice With Brandon Ge and Ty Kayam

Ge Adds Health Data Privacy, Cybersecurity, and AI Governance Depth

Kayam, FDA Digital Health Center of Excellence’s First Attorney, Brings Digital Health and AI Regulatory Experience

WASHINGTON & SEATTLE--(BUSINESS WIRE)--Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that Brandon Ge has joined the firm as senior counsel in Washington, D.C., and Ty Kayam has joined as Of Counsel in Seattle, expanding the firm’s

healthcare regulatory team. The additions reflect growing client demand for integrated counsel spanning health data privacy, cybersecurity, AI governance, digital health, U.S. Food and Drug Administration (FDA) matters, and the regulatory issues shaping product development and healthcare technology transactions.

“A successful health innovation and AI strategy requires a sound data and regulatory approach,” said Jodi Daniel, chair of Wilson Sonsini's Healthcare Regulatory practice. “Innovation in healthcare is moving faster than regulation, and companies need seasoned counsel who understand evolving legal requirements and can provide strategic judgment to navigate complexity. Brandon brings deep experience in health privacy, cybersecurity, and AI governance, while Ty adds a distinctive combination of FDA and private-sector experience in digital health and emerging technologies. Together, they further strengthen our leading Healthcare Regulatory practice and enhance our ability to help clients manage risk, overcome regulatory challenges, and bring their products to market.”

Brandon Ge — Senior Counsel, Washington, D.C.

Ge advises healthcare and technology companies on data privacy, cybersecurity, and AI governance, including incident response, interoperability and information blocking, data use and exchange, and privacy-related contracting.

His experience includes counseling clients on the Health Insurance Portability and Accountability Act (HIPAA), 42 C.F.R. Part 2, the Health Breach Notification Rule, the Federal Trade Commission (FTC) Act, and state and international privacy laws, as well as representing clients in regulatory investigations before the U.S. Department of Health and Human Services (HHS) Office for Civil Rights and state attorneys general.

Ge also led privacy and security due diligence for healthcare and technology transactions, including numerous acquisitions by one of the nation’s largest health insurers and a multibillion-dollar acquisition by one of the world’s largest technology companies. He holds CIPP/US, CIPM, and AIGP certifications.

“Companies used to address privacy and cybersecurity after a deal closed, or after an incident,” said Ge. “That has changed fundamentally—these issues now influence how health technology companies build products, which transactions move forward and on what terms, and how companies respond to regulatory scrutiny. I look forward to working alongside Wilson Sonsini’s talented attorneys to help clients address these issues proactively as they build, transact, and grow.”

Ge received his J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar and articles editor of the Columbia Science and Technology Law Review, and his B.A. from the University of Maryland, College Park.

Ty Kayam — Of Counsel, Seattle

Kayam advises companies and investors on regulatory strategy for health technology products, with a particular focus on health AI, digital health, wearables, medical robotics, and health data infrastructure. She counsels clients throughout product development and commercialization, as well as on health regulatory issues arising in financings, investments, partnerships, and strategic transactions.

Kayam joins Wilson Sonsini after serving as the first attorney in the FDA’s Digital Health Center of Excellence, where she helped shape the agency’s approach to software and AI-enabled medical technologies, including evidentiary expectations, predetermined change control plans, and pre- and post-market considerations. Previously, she was senior corporate counsel at Microsoft, where she advised product, engineering, and business teams developing health technologies, including products incorporating generative AI and foundation models. She also helped develop Microsoft’s global regulatory and policy strategy for its health business.

“Regulatory strategy for a health technology product cannot be separated from how the product is designed and deployed,” said Kayam. “Having worked on both sides of the table, I’ve seen how early choices shape regulatory and market readiness. I’m excited to join Wilson Sonsini and help clients build regulatory considerations into their products from day one.”

Kayam received her J.D. from Northeastern University School of Law, where she was an editor of the Northeastern Law Review. She also holds a Master of Public Health from Tufts University and a B.S. from Acadia University.

About Wilson Sonsini Goodrich & Rosati

For more than 65 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has more than 1,000 attorneys and 17 offices in 16 technology, business, and regulatory markets across the United States, Asia, and Europe. For more information, please visit www.wsgr.com.